Skip to main content

Table 2 Characteristics of 11 patients with not evaluable or uncertain brain response

From: Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea

Case No Study drug started Study drug ended Reason for ending drugs Best systemic response Brain PD by symptoms and MRI Reason for not evaluable brain response during study period Inclusion*
1 Consent withdrawal       ●
2 2007.3.22 2007.3.29 Unknown Unknown Unknown No follow-up MRI ●
3 2008.2.19 2008.3.11 Unknown Unknown Unknown No follow-up MRI ●
4 2008.2.15 2008.4.1 Systemic PD PD Unknown No follow-up MRI ●
5 2007.3.22 2007.4.17 Systemic PD PD Unknown No follow-up MRI ●
6 2007.8.07 2007.9.17 Systemic PD PD 2008.2.18 MRI long after ending study drug ●, ◊
7 2007.4.02 2008.5.21 Brain PD PR 2008.6.3 No MRI until brain symptoms ●, ◊
8 2007.3.30 2007.6.28 Systemic PD PR 2007.11.12 Metastatectomy prior to study started ◊
9 2007.11.30 2008.2.5 Systemic PD SD < 6mo 2008.7.30 Metastatectomy prior to study started ◊
10 2008.4.8 2008.11.11 Systemic PD SD ≥ 6mo 2008.11.7 Metastatectomy prior to study started ◊
11 2007.9.5 2007.12.31 Systemic PD SD < 6mo 2008.2.3 Gamma knife surgery prior to study started ◊
  1. * Included denominator for ●, brain response rate; ◊, brain PFS analysis.
  2. These 11 patients excluded the association between brain response and systemic response (Table 3).
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us